CoChat

Low-dose oral imatinib in the treatment of systemic sclerosis interstitial lung disease unresponsive to cyclophosphamide: a phase II pilot study

Open access

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

Abstract

Introduction: Pulmonary involvement represents a major cause of death of systemic sclerosis (SSc) patients. Recent data suggest that tyrosine kinase inhibitors, such as imatinib, may be a therapeutic option for SSc patients. However, preliminary published clinical trials were inconclusive about imatinib efficacy and showed side effects. The purpose of this study was to verify efficacy and tolerability of low-dose imatinib on interstitial lung disease in a cohort of SSc patients unresponsive to cyclophosphamide therapy. Methods: Thirty consecutive SSc patients with active pulmonary involvement, unresponsive to cyclophosphamide, were treated with imatinib 200 mg/day for 6 months followed by a 6-month follow-up. A “good response” was defined as an increase of forced vital capacity (FVC) by more of 15% and/or increase of diffusing capacity of carbon monoxide (DL CO) >15% and PaO 2 > 90% of initial value and high-resolution computed tomography (HRCT)-scan pattern unchanged or improved. Results: Twenty-six patients completed the study. Three patients died and one patient was lost to follow-up. Four patients (15.32%) had a good response, 7 worsened and 15 had a stabilized lung disease. Overall, 19 (73.07%) patients had an improved or stabilized lung disease. After a 6-month follow-up, 12 (54.5%) of the 22 patients showed an improved or stabilized lung disease. Conclusions: Lung function was stabilized in a large proportion of patients unresponsive to cyclophosphamide therapy and a beneficial outcome emerged from the analysis of HRCT lung scans. There was no significant improvement of skin involvement, and the low dose was well tolerated. These data provide useful suggestions to design future randomized clinical trials for SSc therapeutics. Trial registration: ClinicalTrials.gov NCT00573326. Registered 13 December 2007.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/ar4606

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Trial profile. Six-month data were obtained on all but four patients. At 12-month visit, pulmonary function tests were available in 22 patients. PNX, pneumothorax.
Figure 1 Trial profile. Six-month data were obtained on all but four patients. At 12-month visit, pulmonary function tests were available in 22 patients. PNX, pneumothorax.CC BY · PubMed Central
Figure 2 Number of lung segments with high-resolution computed tomography ground-glass opacities and honeycombing in all patients at baseline and at 6 months. Number of lung segments with high-resolution computed tomography ground-glass opacities (A) and honeycombing (B) in all 26 patients at baseline and at 6 months (T6), and in the subgroups of patients classified as improved, stabilized, and worsened after 6 months of treatment with imatinib (C). (A), (B) Data expressed as median with interquartile ranges. (C) Data expressed as absolute numbers of lung segments.
Figure 2 Number of lung segments with high-resolution computed tomography ground-glass opacities and honeycombing in all patients at baseline and at 6 months. Number of lung segments with high-resolution computed tomography ground-glass opacities (A) and honeycombing (B) in all 26 patients at baseline and at 6 months (T6), and in the subgroups of patients classified as improved, stabilized, and worsened after 6 months of treatment with imatinib (C). (A), (B) Data expressed as median with interquartile ranges. (C) Data expressed as absolute numbers of lung segments.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 33 references

Research works printed but not linked: 1

  1. Carroll M, Ohno-Jones S, Tamura S, Buchdunger E, Zimmermann J, Lydon NB, Gilliand DG, Druker BJ: CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood. 1997, 15: 4947-4952. · DOI · Paper page

Cited by

Items 101–109 of 109

Metadata

Authors
Fraticelli, P., Gabrielli, B., Pomponio, G., Valentini, G., Bosello, S., Riboldi, P., Gerosa, M., Faggioli, P., Giacomelli, R., Del Papa, N., Gerli, R., Lunardi, C., Bombardieri, S., Malorni, W., Corvetta, A., Moroncini, G., & Gabrielli, A.
Affiliations
  • Azienda Ospedaliero-Universitaria delle Marche (IT)
  • University of Campania "Luigi Vanvitelli" (IT)
  • Università Cattolica del Sacro Cuore (IT)
  • University of Milan (IT)
  • Azienda Ospedaliera Ospedale Civile di Legnano (IT)
  • University of L'Aquila (IT)
  • University of Perugia (IT)
  • University of Verona (IT)
  • University of Pisa (IT)
  • Istituto Superiore di Sanità (IT)
  • Ospedale Infermi di Rimini (IT)
  • Marche Polytechnic University (IT)
Corresponding author
Gabrielli, Armando
Venue
Arthritis Research & Therapy
Published
2014-07-08
Volume
16
Issue
4
Pages
R144-R144
ISSN
1478-6354 (ISSN-L)
OpenAlex
W2126719591
Cited by
108
References
33
Citations by year
2025: 4 · 2024: 5 · 2023: 2 · 2022: 7 · 2021: 9 · 2020: 12 · 2019: 14 · 2018: 14 · 2017: 12 · 2016: 18 · 2015: 9
FWCI
9.65
Type
journal article
Language
en
Open access
Licence
Locations
  • Arthritis Research & Therapy (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Archivio Istituzionale della Ricerca - Università degli Studi dell Aquila (submittedVersion, cc-by)
  • Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
  • Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
  • Università Politecnica delle Marche (Università Politecnica delle Marche) (submittedVersion)
  • PubliCatt (Università Cattolica del Sacro Cuore) (submittedVersion, other-oa)
Funders
  • Istituto Superiore di Sanità
  • Università Cattolica del Sacro Cuore
  • Istituto Auxologico Italiano
Topics
  • Health Sciences › Medicine › Rheumatology › Systemic Sclerosis and Related Diseases
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
Keywords
systemic sclerosis, interstitial lung disease, imatinib, tyrosine kinase inhibitors, pulmonary involvement, lung function, forced vital capacity, diffusing capacity for carbon monoxide, high-resolution computed tomography, drug tolerability, skin involvement
MeSH terms
Imatinib Mesylate, Administration, Oral, Adult, Benzamides, Cyclophosphamide, Female, Humans, Immunosuppressive Agents, Male, Middle Aged, Pilot Projects, Piperazines, Pyrimidines, Respiratory Function Tests, Scleroderma, Systemic, Tomography, X-Ray Computed, Treatment Outcome, Lung Diseases, Interstitial, Protein Kinase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.